Evidence map›Paper›PMID 28008176›Full record

ArticleLeukemia2017

Trends in overall survival and costs of multiple myeloma, 2000-2014.

R Fonseca, S Abouzaid, M Bonafede, Q Cai, K Parikh, L Cosler, P Richardson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Availability of pharmacological treatments for multiple myeloma in Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  19. Review
  20. Article

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

R FonsecaMayo Clinic, Phoenix, AZ, USA.
S AbouzaidCelgene Corporation, Summit, NJ, USA.
M BonafedeHealth Economics and Outcomes Research, Truven Health Analytics Inc., an IBM company, Cambridge, MA, USA.
Q CaiHealth Economics and Outcomes Research, Truven Health Analytics Inc., an IBM company, Cambridge, MA, USA.
K ParikhCelgene Corporation, Summit, NJ, USA.
L CoslerBinghamton University, Binghamton, NY, USA.
P RichardsonDana Farber Cancer Institute, Boston, MA, USA.

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive 2 years than those diagnosed in 2006. MM patients showed improved survival over the study period, with the 2-year survival gap between MM patients and matched controls decreasing at a rate of 3% per year. Total costs among MM patients have increased in all healthcare services over the years; however, the relative contribution of drug costs has remained fairly stable since 2009 despite new novel therapies coming to market. Findings from this study corroborate clinical data, suggesting a paradigm shift in MM treatment over the past decade that is associated with substantial survival gains. Future studies should focus on the impact on specific novel agents on patients' outcomes.

Indexed as

Costs and Cost AnalysisDelivery of Health CareDrug CostsHumansMultiple MyelomaSurvival RateTreatment OutcomeUnited States

Identifiers

PMID28008176
PMCPMC5596206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.